Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
215600.KQ
STRONG SELLSillaJen, Inc. · Healthcare · South Korea · $233M · Avg Vol: $1M/d
13
StockRankQ
39
V
37
M
24
P/E (TTM)
—
ROE
-20.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 3M | 3M | 3M | 6M | 22.5% |
| EPS | — | -0.14 | -0.12 | -0.14 | -0.12 | — |
| Shares | — | 113M | 113M | 137M | 138M | +22.0% |
| Debt | 4M | 10M | 6M | 7M | 1M | -20.7% |
| Equity | — | 52M | 38M | 87M | 72M | 11.7% |
| Op CF | — | -15M | -11M | -12M | -15M | — |
| Inv CF | — | -7M | 24M | -17M | -30M | — |
| Fin CF | — | -3M | -5M | 66M | -5M | — |
Loading...
PRICE (1M)-26.2%
SMA 50SMA 200
Close
$1.62
RSI (14)
23.9
52W High
$3.55
From 52W High
0.5%
SCORE BREAKDOWN
Quality
39
ROIC
-20.6%27.9
ROE
-20.8%29.5
GP/Assets
6.0%20.1
Op. Margin
-198.1%13.8
FCF/Assets
-16.9%19.9
Piotroski
—28.7
Int. Cover
-25.4x18.3
D/E Ratio
0.02x82.2
Current Ratio
15.81x93.1
Value
37
P/E (TTM)
—N/A
EV/EBITDA
-10.3x81.8
P/FCF
—N/A
P/B
3.2x37.7
P/S
32.3x12.3
Div Yield
—N/A
Momentum
24
52W High %
45%18.8
RS 6M
-148%3.5
SMA 50/200
0.98x58.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$233M
P/E (Forward)
—
Gross Margin
63.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 215600.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 215600.KQ | SillaJen, Inc.(you) | $233M | 13 | STRONG SELL |
| 389650.KQ | NEXTBIOMEDICAL | $217M | 12 | STRONG SELL |
| 304360.KQ | S.Biomedics Co., Ltd. | $225M | 9 | STRONG SELL |
| 199800.KQ | ToolGen Incorporated | $266M | 11 | STRONG SELL |
| 228760.KQ | Genomictree Inc. | $216M | 9 | STRONG SELL |
| 217730.KQ | Kangstem Biotech Co., Ltd. | $189M | 18 | STRONG SELL |
| 138610.KQ | NIBEC Co., Ltd. | $141M | 14 | STRONG SELL |
| 115450.KQ | HLB Therapeutics Co.,Ltd. | $147M | 15 | STRONG SELL |
| 287840.KQ | IntoCell, Inc. | $227M | 2 | STRONG SELL |
| 308080.KQ | ViGenCell Inc. | $135M | 12 | STRONG SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.4%